0.81
0.81 (0%)
As of Feb 14, 2025
Spero Therapeutics, Inc. [SPRO]
Source:
Company Overview
Spero Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (“MDR”) bacterial infections with high unmet need.
| Country | United States |
| Headquarters | cambridge, massachusetts |
| Phone Number | (857) 242-1600 |
| Industry | manufacturing |
| CEO | Satyavrat Shukla |
| Website | www.sperotherapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $48 |
| Operating Profit | $-73.4 |
| Net Income | $-68.6 |
| Net Cash | $-23.4 |
Profit Ratios
| Gross Margin | $48 |
| Operating Margin | -152.9 |
| Profit as % of Revenues | -70% |
| Profit as % of Assets | -46.8% |
| Profit as % of Stockholder Equity | -148.7% |
Management Effectiveness
| Return on Equity | -148.7% |
| Return on Assets | -62% |
| Turnover Ratio | 32.8% |
| EBITA | $-73.4 |
Balance Sheet and Cash Flow Measures
| Total Assets | $110.5 |
| Total Liabilities | $64.4 |
| Operating Cash Flow | $-23.4 |
| Investing Cash Flow | |
| Financing Cash Flow | $0 |
